Back

Cardiac resynchronisation therapy and implantable cardioverter-defibrillator in non-ischaemic systolic heart failure: extended follow-up of the DANISH trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Heart failure: let’s re-synchronise please Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Adelina Yafasova

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

5 More presentations in this session

Presentation thumbnail
Cardiac resynchronization therapy: association between genetically determinated dilated cardiomyopathy and dissinchronopathy
Doctor M. Zecchin (Trieste, IT)
Abstract Slides Video
Presentation thumbnail
Impact of cardiac resynchronisation therapy in patients with cardiac sarcoidosis
Doctor R. Ahmed (Newcastle-Upon-Tyne, GB)
Abstract Slides Video
Presentation thumbnail
The impact of right ventricular size and function on long-term outcomes in patients undergoing cardiac resynchronization therapy
Mr X. Galloo (Brussels, BE)
Abstract Slides Video
Presentation thumbnail
Biventricular or left univentricular pacing in heart failure patients: is there a better strategy
Doctor M. Barradas (Ponta Delgada, PT)
Abstract Slides Video
Presentation thumbnail
Prediction of response to cardiac resynchronization therapy using cardiac magnetic resonance imaging in non-ischemic dilated cardiomyopathy
Doctor S. Kim (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure: let’s re-synchronise please

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Do we need a prophylactic ICD in patients with CRT indication? pro
thumbnail
Congress Presentation
Atrial fibrillation/flutter may modify the long-term effect of primary prevention implantable cardioverter-defibrillators in non-ischemic HFrEF: an extended follow-up study of the DANISH trial
thumbnail
Congress Presentation
Primary prevention implantable cardioverter defibrillators are no longer indicated in non-ischaemic HFrEF: pro

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources